Kinexum guides, designs, and manages strategic and operational solutions to the regulatory, manufacturing, nonclinical, clinical development, and business challenges necessary to take scientific discoveries to proof of concept and through the product life cycle.
Kinexum teams supplement the strengths of large and small organizations to reach high-value milestones effectively and efficiently. Kinexum specializes in crafting creative but sound and integrated solutions across scientific disciplines, therapeutic areas, product modalities, and business stages. We respond to emergencies and as well as requests for problem prevention and complex long-range planning.
NEWS AND UPCOMING EVENTS.
"Wow or Yeow!?: 2021 Outlook for FDA" is now available. Click on the following links to view. VIDEO CHAT TRANSCRIPT
UPCOMING WEBINARS and CONFERENCES
Browse our Upcoming Meetings to see where and when you can hear Kinexum Executive Chairman and Founder, Dr. Zan Fleming, speak or if interested, meet with a Kinexum Team Member.
KINEXION NEWSLETTER
Featured Articles From Our Desks
LATEST PUBLISHED ARTICLE! The Need for Precision Medicine to be Applied to Diabetes. Alexander Fleming, MD, David C. Klonoff, MD, FACP, FRCP (Edin), Jose C. Florez, MD, PhD, and Michael German, MD.
Spanning pharmaceuticals, biologics, and devices, we have supported over 250 clients during the past decade to achieve their goals. Kinexum uniquely brings together:
We specialize in chronic metabolic diseases including diabetes, obesity, oncology, immunology, cardiometabolic, neuropathy and their complications.
Kinexum has provided support over the past decade to many of the leading companies developing therapies for diabetes, obesity and metabolism and a growing list of oncology and cardiovascular companies. With high unmet needs and growing healthcare costs, innovative and personalized approaches for the treatment of chronic metabolic diseases are of high value and interest.
Today, translational research and development faces what has been called the “valley of death”—the precarious, day to day challenge of managing high costs and risks of early stage development with limited resources. Traversing this stage of health product development requires an integrated strategy for achieving regulatory, preclinical, CMC, and clinical objectives.
Efficient utilization of limited resources is required to create value that will maintain funding momentum. Kinexum professionals are experts in supplementing the technical, operational, and business needs of a small company.
Kinexum provides a personalized approach to understanding and meeting the challenges and obstacles faced by science-driven organizations.